DK1360504T3 - Fremgangsmåde til screening af forbindelser for aktivitet ved behandling af en osteoclast-relateret knoglesygdom - Google Patents

Fremgangsmåde til screening af forbindelser for aktivitet ved behandling af en osteoclast-relateret knoglesygdom

Info

Publication number
DK1360504T3
DK1360504T3 DK02715378T DK02715378T DK1360504T3 DK 1360504 T3 DK1360504 T3 DK 1360504T3 DK 02715378 T DK02715378 T DK 02715378T DK 02715378 T DK02715378 T DK 02715378T DK 1360504 T3 DK1360504 T3 DK 1360504T3
Authority
DK
Denmark
Prior art keywords
treatment
osteoclast
activity
related bone
bone disease
Prior art date
Application number
DK02715378T
Other languages
Danish (da)
English (en)
Inventor
Anne Marie Heegaard
Michael Thyrring Engsig
Lars Siim Madsen
Bo Skaaning Jensen
Palle Christophersen
Martin Stahlhut
Morten Asser Karsdal
Original Assignee
Pharmos Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmos Bioscience As filed Critical Pharmos Bioscience As
Application granted granted Critical
Publication of DK1360504T3 publication Critical patent/DK1360504T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK02715378T 2001-01-23 2002-01-17 Fremgangsmåde til screening af forbindelser for aktivitet ved behandling af en osteoclast-relateret knoglesygdom DK1360504T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200100118 2001-01-23
US26587401P 2001-02-05 2001-02-05
PCT/DK2002/000037 WO2002059356A2 (en) 2001-01-23 2002-01-17 Method for screening compounds for activity in treating an osteoclast related bone disease

Publications (1)

Publication Number Publication Date
DK1360504T3 true DK1360504T3 (da) 2007-01-29

Family

ID=26068950

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02715378T DK1360504T3 (da) 2001-01-23 2002-01-17 Fremgangsmåde til screening af forbindelser for aktivitet ved behandling af en osteoclast-relateret knoglesygdom

Country Status (8)

Country Link
US (1) US20040224881A1 (de)
EP (1) EP1360504B1 (de)
JP (1) JP2004522441A (de)
AT (1) ATE339690T1 (de)
AU (1) AU2002224758A1 (de)
DE (1) DE60214673T2 (de)
DK (1) DK1360504T3 (de)
WO (1) WO2002059356A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215787A1 (en) * 2002-01-23 2003-11-20 Wen-Pin Yang Modulators of the CLC-7 chloride channel and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
GB0227243D0 (en) * 2002-11-21 2002-12-31 Univ Aberdeen Genetic markers for bone mass
GB0525898D0 (en) 2005-12-20 2006-02-01 Pharmo Bioscience As Screening compounds for activity in modulating chloride ion transport
EP2420830B1 (de) 2010-08-16 2016-11-16 Forschungsverbund Berlin e.V. Chloridtransporter ClC-7 und zellbasiertes Screening-Verfahren
JP6261048B2 (ja) * 2012-12-05 2018-01-17 国立大学法人 新潟大学 破骨細胞が関与する疾患の予防又は治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1514867A3 (de) * 1998-10-22 2005-03-23 NeuroSearch A/S Substituierte Phenylderivate, ihre Herstellung und Verwendung
US7399599B2 (en) * 2000-07-10 2008-07-15 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods
DE10102977A1 (de) * 2001-01-23 2002-08-01 Thomas Jentsch Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose

Also Published As

Publication number Publication date
EP1360504A2 (de) 2003-11-12
AU2002224758A1 (en) 2002-08-06
US20040224881A1 (en) 2004-11-11
WO2002059356A3 (en) 2003-05-01
JP2004522441A (ja) 2004-07-29
ATE339690T1 (de) 2006-10-15
DE60214673T2 (de) 2007-09-13
WO2002059356A2 (en) 2002-08-01
EP1360504B1 (de) 2006-09-13
DE60214673D1 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
EP1636359A4 (de) Verfahren zur schmerzbehandlung
ATE478082T1 (de) Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
BRPI0307673A2 (pt) métodos de tratar doença vascular.
EA200700336A1 (ru) Противовирусные соединения
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DK1385826T3 (da) Fremgangsmåde til fremstilling af (S)-(+)- og (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azapin-5-carboxamid
EA200601217A1 (ru) Новые конденсированные пирролокарбазолы
EP1392332A4 (de) Verfahren zur zerstörung von oozysten
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
NO20055741L (no) Nye kjemiske forbindelser
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
EP1868437A4 (de) Verfahren zur behandlung oder verhinderung von knochenabbau oder osteoporose
BR0200467B1 (pt) mÉtodo de tratamento quÍmico de fosfato eletrolÍtico.
EP1389105A4 (de) Behandlungsverfahren
DE60207811D1 (de) Zusammensetzungen zur entfernung von menschlichem cerumen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole